Asia Pacific Bioproduction Market Forecast to 2030

Asia Pacific Bioproduction Market Forecast to 2030

Asia Pacific Bioproduction Market Forecast to 2030 – Regional Analysis – by Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), and End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others)

Send Enquiry
Item ID: BMIRE00030060 Category: Tag:

$2,485 – $3,885

Description

The Asia Pacific bioproduction market was valued at US$ 4,791.34 million in 2022 and is expected to reach US$ 14,612.30 million by 2030; it is estimated to register a CAGR of 15.0% from 2022 to 2030.

Patent Expiry of Blockbuster Biologics Boosts Asia Pacific Bioproduction Market

Biologicals represent promising new therapies for previously incurable diseases and are becoming highly important in the pharmaceuticals market. Patents on originator biologicals are expected to expire in the coming years.

Estimated patent and exclusivity expiry dates for best-selling biologicals are given in the following table.

Biologicals Expiry Dates

Biologicals Expiry Dates

Avastin January 2022

Cyramza May 2023

Adcetris August 2023

Abthrax October 2024

Gazyva/Gazyvaro November 2024

Darzalex May 2026

Ocrevus April 2027

Emgality September 2028

Hemlibra February 2028

Llumetri March 2028

Imfinzi September 2028

Mylotarg April 2028

Imfinzi September 2028

Mylotarg April 2028

Sylvant July 2034

The patent expiration and other intellectual property rights for originator biologicals will create a need to introduce new biosimilars in the future. As a result, competition among market players will surge in the industry in the coming years. Thus, the patent expiry of blockbuster biologics is expected to create lucrative opportunities for the bioproduction market during the forecast period.

Asia Pacific Bioproduction Market Overview

The Asia Pacific bioproduction market is segmented into China, Japan, India, South Korea, Australia, South Korea, and the Rest of Asia Pacific. The growth of the market in Asia Pacific is anticipated to grow at a faster pace owing to factors such as growing need for superior treatment solutions, increasing focus on research and development activities, and favorable regulatory scenarios. Additionally, increasing investments and developing healthcare infrastructure to boost research activities are estimated to drive the Asia Pacific bioproduction market during 2022-2030.

In China, the demand for healthcare is increasing rapidly. Factors such as growing geriatric population, rising incidence of chronic diseases, and increasing government initiatives in the healthcare sector are driving the cell therapy market in China. Improvements in basic and private medical insurance plans have also accelerated the growth of the medical sector in the country. The rising income levels have led to the demand for more sophisticated healthcare services. The rise in the geriatric population has led to an increase in the specialty medical community in the country. In China, the growing prevalence of cancer is likely to increase the adoption of cell therapy. According to the National Central Cancer Registry of China, 4.3 million new cancer cases were registered in China.

Asia Pacific Bioproduction Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Bioproduction Market Segmentation

The Asia Pacific bioproduction market is categorized into product, application, equipment, end user, and country.

Based on product, the Asia Pacific bioproduction market is segmented into biologics and biosimilars, vaccines, cell and gene therapies, nucleic acid therapeutics, and others. The biologics and biosimilars segment held the largest Asia Pacific bioproduction market share in 2022.

In terms of application, the Asia Pacific bioproduction market is segmented into rheumatoid arthritis, hematological disorders, cancer, diabetes, cardiovascular diseases, and others. The cancer segment held the largest Asia Pacific bioproduction market share in 2022.

By equipment, the Asia Pacific bioproduction market is divided into upstream equipment, downstream equipment, bioreactors, and consumables and accessories. The consumables and accessories segment held the largest Asia Pacific bioproduction market share in 2022.

In terms of end user, the Asia Pacific bioproduction market is categorized into biopharmaceutical companies, contract manufacturing organizations, and others. The biopharmaceutical companies segment held the largest Asia Pacific bioproduction market share in 2022.

By country, the Asia Pacific bioproduction market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific bioproduction market share in 2022.

Lonza Group AG, bbi-biotech GmbH, Danaher Corp, Sartorius AG, FUJIFILM Irvine Scientific Inc, Thermo Fisher Scientific Inc, Merck KGaA, F. Hoffmann-La Roche Ltd, and Bio-Rad Laboratories Inc. are some of the leading companies operating in the Asia Pacific bioproduction market.

Summary Info

Industry:

Pricing options:

, ,

Geographical coverage:

, ,

Year of Publication:

At 15.0% CAGR, Asia Pacific Bioproduction Market is Speculated to be Worth US$ 14,612.30 Million by 2030, says the Research Team

According to the Research Team’ research, the Asia Pacific bioproduction market was valued at US$ 4,791.34 million in 2022 and is expected to reach US$ 14,612.30 million by 2030, registering a CAGR of 15.0% from 2022 to 2030. Patent expiry of blockbuster biologics and increasing prevalence of chronic diseases are among the critical factors attributed to drive the Asia Pacific bioproduction market growth.

Cardiovascular diseases (CVDs), neurological disorders, autoimmune disorders, and cancer are among the chronic diseases causing death and disabilities at a significant rate worldwide. As per the World Health Organization (WHO), CVDs are the number 1 cause of death globally, taking an estimated 17.9 million lives each year. Cancer is also among the leading causes of mortality worldwide, affecting a huge population; therefore, it acts as a huge financial burden on society. According to the WHO, in 2020, ~10 million deaths occurred due to cancer globally. However, growing research on developing effective treatments for the disease is positively affecting the market growth. Gene therapy and cell therapy are transforming the cancer treatment landscape; for example, Novartis’ Kymriah is used to treat diffuse large B-cell lymphoma.

Moreover, recognition of biosimilars as efficacious and safe agents by patients, specialists, primary care clinicians, and other healthcare professionals is propelling the demand for biosimilars. In addition, biosimilars help improve life of millions of patients while saving billions of dollars of the healthcare system per year. They are effective and cost-effective options in treating many diseases, including chronic skin conditions and bowel diseases such as Crohn’s disease, psoriasis, irritable bowel syndrome, and colitis; diabetes; autoimmune disease; cancer; kidney conditions; and arthritis.

As the prevalence of chronic diseases is increasing at a high rate, the demand for bioproduction in treating life-threatening illnesses has progressed rapidly over the last five years, thereby driving the bioproduction market.

On the contrary, high cost of cell therapy and biosimilar manufacturing hampers the growth of Asia Pacific bioproduction market.

Based on product, the Asia Pacific bioproduction market is segmented into biologics and biosimilars, vaccines, cell and gene therapies, nucleic acid therapeutics, and others. The biologics and biosimilars segment held 38.2% Asia Pacific bioproduction market share in 2022, amassing US$ 1,829.29 million. It is projected to garner US$ 5,223.08 million by 2030 to register 14.0% CAGR during 2022-2030.

In terms of application, the Asia Pacific bioproduction market is segmented into rheumatoid arthritis, hematological disorders, cancer, diabetes, cardiovascular diseases, and others. The cancer segment held 37.8% share of Asia Pacific bioproduction market in 2022, amassing US$ 1,813.27 million. It is anticipated to garner US$ 5,757.07 million by 2030 to expand at 15.5% CAGR during 2022-2030.

By equipment, the Asia Pacific bioproduction market is divided into upstream equipment, downstream equipment, bioreactors, and consumables and accessories. The consumables and accessories segment held 39.4% share of Asia Pacific bioproduction market in 2022, amassing US$ 1,888.96 million. It is projected to garner US$ 6,088.83 million by 2030 to expand at 15.8% CAGR from 2022 to 2030.

In terms of end user, the Asia Pacific bioproduction market is categorized into biopharmaceutical companies, contract manufacturing organizations, and others. The biopharmaceutical companies segment held 53.8% share of Asia Pacific bioproduction market in 2022, amassing US$ 2,577.74 million. It is projected to garner US$ 7,778.23 million by 2030 to expand at 14.8% CAGR from 2022 to 2030.

Based on country, the Asia Pacific bioproduction market is categorized into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 30.0% share of Asia Pacific bioproduction market in 2022. It was assessed at US$ 1,437.88 million in 2022 and is likely to hit US$ 4,502.05 million by 2030, registering a CAGR of 15.3% during 2022-2030.

Key players operating in the Asia Pacific bioproduction market are Lonza Group AG, bbi-biotech GmbH, Danaher Corp, Sartorius AG, FUJIFILM Irvine Scientific Inc, Thermo Fisher Scientific Inc, Merck KGaA, F. Hoffmann-La Roche Ltd, and Bio-Rad Laboratories Inc., among others.

o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific bioproduction market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific bioproduction market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific bioproduction market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Bioproduction Market – Key Industry Dynamics
4.1 Market Drivers
4.1.1 Rising Adoption of Regenerative Medicines
4.1.2 Increasing Prevalence of Chronic Diseases
4.2 Market Restraints
4.2.1 High Cost of Cell Therapy and Biosimilar Manufacturing
4.3 Market Opportunities
4.3.1 Patent Expiry of Blockbuster Biologics
4.4 Future Trends
4.4.1 Shift Toward Automated Cell Therapy Manufacturing
4.5 Impact Analysis
5. Bioproduction Market – Asia Pacific Market Analysis
5.1 Asia Pacific Bioproduction Market Revenue (US$ Mn), 2020 – 2030
6. Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 – by Product
6.1 Overview
6.2 Asia Pacific Bioproduction Market Revenue Share, by Product 2022 & 2030 (%)
6.3 Biologics and Biosimilars
6.3.1 Overview
6.3.2 Biologics and Biosimilars: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Vaccines
6.4.1 Overview
6.4.2 Vaccines: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
6.5 Cell and Gene Therapies
6.5.1 Overview
6.5.2 Cell and Gene Therapies: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
6.6 Nucleic Acid Therapeutics
6.6.1 Overview
6.6.2 Nucleic Acid Therapeutics: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
6.7 Others
6.7.1 Overview
6.7.2 Others: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
7. Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 – by Application
7.1 Overview
7.2 Asia Pacific Bioproduction Market Revenue Share, by Application 2022 & 2030 (%)
7.3 Cancer
7.3.1 Overview
7.3.2 Cancer: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Cardiovascular Diseases
7.4.1 Overview
7.4.2 Cardiovascular Diseases: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Rheumatoid Arthritis
7.5.1 Overview
7.5.2 Rheumatoid Arthritis: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Hematological Disorders
7.6.1 Overview
7.6.2 Hematological Disorders: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
7.7 Diabetes
7.7.1 Overview
7.7.2 Diabetes: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
7.8 Others
7.8.1 Overview
7.8.2 Others: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 – by Equipment
8.1 Overview
8.2 Asia Pacific Bioproduction Market Revenue Share, by Equipment 2022 & 2030 (%)
8.3 Consumables and Accessories
8.3.1 Overview
8.3.2 Consumables and Accessories: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Downstream Equipment
8.4.1 Overview
8.4.2 Downstream Equipment: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Bioreactors
8.5.1 Overview
8.5.2 Bioreactors: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
8.5.2.1 Asia Pacific: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
8.6 Upstream Equipment
8.6.1 Overview
8.6.2 Upstream Equipment: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 – by End User
9.1 Overview
9.2 Asia Pacific Bioproduction Market Revenue Share, by End User 2022 & 2030 (%)
9.3 Biopharmaceutical Companies
9.3.1 Overview
9.3.2 Biopharmaceutical Companies: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Contract Manufacturing Organizations
9.4.1 Overview
9.4.2 Contract Manufacturing Organizations: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10. Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 – Country Analysis
10.1 Asia Pacific: Bioproduction Market
10.1.1 Asia Pacific: Bioproduction Market, by Country, 2022 & 2030 (%)
10.1.1.1 China: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.1 China: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.2 China: Bioproduction Market, by Product, 2020-2030 (US$ Million)
10.1.1.1.3 China: Bioproduction Market, by Application, 2020-2030 (US$ Million)
10.1.1.1.4 China: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
10.1.1.1.4.1 China: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
10.1.1.1.5 China: Bioproduction Market, by End User, 2020-2030 (US$ Million)
10.1.1.2 India: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 India: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.3 India: Bioproduction Market, by Product, 2020-2030 (US$ Million)
10.1.1.2.4 India: Bioproduction Market, by Application, 2020-2030 (US$ Million)
10.1.1.2.5 India: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
10.1.1.2.5.1 India: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
10.1.1.2.6 India: Bioproduction Market, by End User, 2020-2030 (US$ Million)
10.1.1.3 Japan: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 Japan: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.3 Japan: Bioproduction Market, by Product, 2020-2030 (US$ Million)
10.1.1.3.4 Japan: Bioproduction Market, by Application, 2020-2030 (US$ Million)
10.1.1.3.5 Japan: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
10.1.1.3.5.1 Japan: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
10.1.1.3.6 Japan: Bioproduction Market, by End User, 2020-2030 (US$ Million)
10.1.1.4 Australia: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.1 Overview
10.1.1.4.2 Australia: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.3 Australia: Bioproduction Market, by Product, 2020-2030 (US$ Million)
10.1.1.4.4 Australia: Bioproduction Market, by Application, 2020-2030 (US$ Million)
10.1.1.4.5 Australia: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
10.1.1.4.5.1 Australia: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
10.1.1.4.6 Australia: Bioproduction Market, by End User, 2020-2030 (US$ Million)
10.1.1.5 South Korea: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.1 Overview
10.1.1.5.2 South Korea: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.3 South Korea: Bioproduction Market, by Product, 2020-2030 (US$ Million)
10.1.1.5.4 South Korea: Bioproduction Market, by Application, 2020-2030 (US$ Million)
10.1.1.5.5 South Korea: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
10.1.1.5.5.1 South Korea: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
10.1.1.5.6 South Korea: Bioproduction Market, by End User, 2020-2030 (US$ Million)
10.1.1.6 Rest of Asia Pacific: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.1 Overview
10.1.1.6.2 Rest of Asia Pacific: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.3 Rest of Asia Pacific: Bioproduction Market, by Product, 2020-2030 (US$ Million)
10.1.1.6.4 Rest of Asia Pacific: Bioproduction Market, by Application, 2020-2030 (US$ Million)
10.1.1.6.5 Rest of Asia Pacific: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
10.1.1.6.5.1 Rest of Asia Pacific: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
10.1.1.6.6 Rest of Asia Pacific: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
11. Bioproduction Market-Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Bioproduction Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 . Lonza Group AG
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 bbi-biotech GmbH
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Danaher Corp
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Sartorius AG
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 FUJIFILM Irvine Scientific Inc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Thermo Fisher Scientific Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Merck KGaA
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 F. Hoffmann-La Roche Ltd
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Bio-Rad Laboratories Inc
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. Appendix
13.1 About Us
13.2 Glossary of Terms

LIST OF TABLES

Table 1. Asia Pacific Bioproduction Market Segmentation
Table 2. Asia Pacific Bioproduction Market, For Bioreactors by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 3. China Bioproduction Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 4. China Bioproduction Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 5. China Bioproduction Market, by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 6. China Bioproduction Market, For Bioreactors by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 7. China Bioproduction Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 8. India Bioproduction Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 9. India Bioproduction Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 10. India Bioproduction Market, by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 11. India Bioproduction Market, For Bioreactors by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 12. India Bioproduction Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 13. Japan Bioproduction Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 14. Japan Bioproduction Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 15. Japan Bioproduction Market, by Equipment- Revenue and Forecast to 2030 (US$ Million)
Table 16. Japan Bioproduction Market, For Bioreactors by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 17. Japan Bioproduction Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 18. Australia Bioproduction Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 19. Australia Bioproduction Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 20. Australia Bioproduction Market, by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 21. Australia Bioproduction Market, For Bioreactors by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 22. Australia Bioproduction Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 23. South Korea Bioproduction Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 24. South Korea Bioproduction Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 25. South Korea Bioproduction Market, by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 26. South Korea Bioproduction Market, For Bioreactors by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 27. South Korea Bioproduction Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 28. Rest of Asia Pacific Bioproduction Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 29. Rest of Asia Pacific Bioproduction Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 30. Rest of Asia Pacific Bioproduction Market, by Equipment- Revenue and Forecast to 2030 (US$ Million)
Table 31. Rest of Asia Pacific Bioproduction Market, For Bioreactors by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 32. Rest of Asia Pacific Bioproduction Market, by Equipment- Revenue and Forecast to 2030 (US$ Million)
Table 33. Recent Inorganic Growth Strategies in the Bioproduction Market
Table 34. Recent Organic Growth Strategies in the Bioproduction Market
Table 35. Glossary of Terms, Bioproduction Market

LIST OF FIGURES

Figure 1. Asia Pacific Bioproduction Market Segmentation, By Country
Figure 2. Asia Pacific Bioproduction Market: Key Industry Dynamics
Figure 3. Asia Pacific Bioproduction Market: Impact Analysis of Drivers and Restraints
Figure 4. Asia Pacific Bioproduction Market Revenue (US$ Mn), 2020 – 2030
Figure 5. Asia Pacific Bioproduction Market Revenue Share, by Product 2022 & 2030 (%)
Figure 6. Biologics and Biosimilars: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Vaccines: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Cell and Gene Therapies: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Nucleic Acid Therapeutics: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Others: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Asia Pacific Bioproduction Market Revenue Share, by Application 2022 & 2030 (%)
Figure 12. Cancer: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Cardiovascular Diseases: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Rheumatoid Arthritis: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Hematological Disorders: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Diabetes: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Asia Pacific Bioproduction Market Revenue Share, by Equipment 2022 & 2030 (%)
Figure 19. Consumables and Accessories: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Downstream Equipment: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Bioreactors: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. Upstream Equipment: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23. Asia Pacific Bioproduction Market Revenue Share, by End User 2022 & 2030 (%)
Figure 24. Biopharmaceutical Companies: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Contract Manufacturing Organizations: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 26. Others: Asia Pacific Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 27. Asia Pacific: Bioproduction Market, by Key Country – Revenue (2022) (US$ Million)
Figure 28. Asia Pacific: Bioproduction Market, by Country, 2022 & 2030 (%)
Figure 29. China: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 30. India: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 31. Japan: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 32. Australia: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 33. South Korea: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 34. Rest of Asia Pacific: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 35. Growth Strategies in the Bioproduction Market

1. Lonza Group AG
2. bbi-biotech GmbH
3. Danaher Corp
4. Sartorius AG
5. FUJIFILM Irvine Scientific Inc
6. Thermo Fisher Scientific Inc
7. Merck KGaA
8. F. Hoffmann-La Roche Ltd
9. Bio-Rad Laboratories Inc

Reviews

There are no reviews yet.

Be the first to review “Asia Pacific Bioproduction Market Forecast to 2030”